Auritec Pharmaceuticals, Inc.
Publicly observedPasadena, United States
Seen in a public record (e.g. a government grant database); not otherwise verified.
Details and provenance
| Item | Value | Source | Status |
|---|---|---|---|
| Country | US | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| City / locality | Pasadena | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| Name | Auritec Pharmaceuticals, Inc. | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| UEI (U.S. federal entity ID) | QX8KP6JKQ2L8 | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
Recorded events
- Grant22 Sept 2026Publicly observed
NIH SBIR/STTR award: Long-acting Injectable Brexpiprazole for Agitation in Alzheimer's Dementia
USD 1,029,519.00 · National Institute on Aging · Source: NIH RePORTER (opens in a new tab)
- Grant1 Feb 2018Publicly observed
NIH SBIR/STTR award: IND-enabling Preclinical Development of a Sustained-release Pritelivir Intravaginal ring for the Treatment and Prophylaxis of Genital Herpes
USD 1,000,000.00 · National Institute of Allergy and Infectious Diseases · Source: NIH RePORTER (opens in a new tab)
Information only — not investment advice or an endorsement. Is this your company? Submit or update its details or request a correction.